Credit Suisse analyst A.J. Rice maintained a Buy rating on Quest Diagnostics Inc (DGX) yesterday and set a price target of $101. The company’s shares closed on Friday at $87.81.
According to TipRanks.com, Rice is a 5-star analyst with an average return of 9.9% and a 65.6% success rate. Rice covers the Services sector, focusing on stocks such as Genesis Healthcare, Acadia Healthcare, and Select Medical.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Quest Diagnostics Inc with a $97 average price target, a 10.5% upside from current levels. In a report issued on February 15, Barclays also maintained a Buy rating on the stock with a $114 price target.
See today’s analyst top recommended stocks >>
Based on Quest Diagnostics Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.84 billion and net profit of $126 million. In comparison, last year the company earned revenue of $1.94 billion and had a net profit of $253 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Quest Diagnostics, Inc. engages in the provision fo diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers.
